ATLASViridian Therapeutics (VRDN) earnings date: Nov 4, 2026
Viridian Therapeutics (VRDN) reports earnings for the quarter ended Sep 30, 2026 on Wed, Nov 4, 2026, before the open. Analysts expect EPS of -$1.08.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on VRDN
| Last price | $24.67 (-0.5%) |
|---|---|
| Normal 1-day range (±1σ) | ±3.3% |
| Earnings beat history | Beat the EPS estimate in 1 of the last 5 reports |
These figures come from the same calibrated model and valuation as the Viridian Therapeutics stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Viridian Therapeutics reports on Nov 4, 2026. One email the day before, with ATLAS’s read on Viridian Therapeutics. You can switch it off at any time.
Alert me before VRDN reportsFree to start. Creating an account takes under a minute.
VRDN earnings at a glance
| Next report (confirmed) | Wed, Nov 4, 2026 |
|---|---|
| Time | Before the open |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | -$1.08 |
| Last report | Aug 6, 2026 · In line |
| Beat rate (last 5 reports) | 1 of 5 (20%) |
| Average EPS surprise | +0.9% |
| Average move around a report | ±8.4% (last 5) |
| Sector | Healthcare · Biotechnology |
Viridian Therapeutics earnings history: last 5 reports
Viridian Therapeutics last reported on Aug 6, 2026: EPS of -$1.05 against an estimate of -$1.03 (-1.9% surprise), in line with the estimate.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Aug 6, 2026 | -$1.03 | -$1.05 | -1.9% | In line | +12.0% |
| May 5, 2026 | -$1.08 | -$0.90 | +16.7% | Beat | +24.7% |
| Apr 13, 2026 | $0.30 | $0.30 | 0.0% | In line | +1.6% |
| Mar 26, 2026 | $1.30 | $1.16 | -10.8% | Miss | -3.4% |
| Mar 12, 2026 | $1.38 | $1.39 | +0.7% | In line | +0.2% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for VRDN
See the fair value, the probability range and the earnings history of Viridian Therapeutics on its ATLAS page.
Viridian Therapeutics (VRDN) stock analysisPlans from €3.99 a month.
Viridian Therapeutics earnings: frequently asked questions
When does Viridian Therapeutics (VRDN) report earnings?
Viridian Therapeutics is scheduled to report on Wednesday, November 4, 2026, before the open. ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for VRDN?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is -$1.08 per share (USD). Estimates can change before the report.
How often does VRDN beat earnings estimates?
Of its last 5 reports with a recorded result, Viridian Therapeutics beat the EPS estimate 1 times; the average surprise was +0.9%. Past results do not predict the next one.
How much does VRDN move around earnings?
Over its last 5 reports the stock moved an average of 8.4% (absolute, from the close before the report day to the close after it), and finished higher 4 of 5 times.
Did Viridian Therapeutics beat earnings estimates last quarter?
Viridian Therapeutics last reported on Aug 6, 2026: EPS of -$1.05 against an estimate of -$1.03 (-1.9% surprise), in line with the estimate.
How much does VRDN usually move in a day?
On a normal trading day the ATLAS model puts VRDN’s one-day range at about ±3.3%, with a 50% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Wed, Nov 4, 2026
Educational information, not investment advice. Disclaimer